NC-KBI-BIOPHARMA
KBI Biopharma, Inc. (KBI), a JSR Life Sciences company and cGMP contract development and manufacturing organization (CDMO), today announced the appointment of Peter Carbone as the new Chief Quality Officer, strengthening KBI’s expertise in Quality and Regulatory Affairs.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240401053397/en/
Peter Carbone, KBI Biopharma Chief Quality Officer (Photo: Business Wire)
A highly respected and successful industry leader, Peter brings over 35 years of experience in operations, quality, and technology leadership in a diverse range of areas in the life sciences spectrum, including biotechnology, pharmaceuticals, and advanced therapies. Peter will lead KBI’s Quality and Regulatory Affairs team, spearheading compliance and regulatory initiatives for customers worldwide and positioning KBI to provide the services, expertise, and leadership to partner with health authorities on regulatory policy.
"We have made a commitment to establishing KBI Biopharma as a thought leader and catalyst for change in Regulatory Affairs within the biopharma sector,” said J.D. Mowery, President & CEO of KBI Biopharma. "Peter's addition to our team bolsters our expertise in quality and regulatory compliance and facilitates our continued transformation in support of our current and future customers. His passion for making a difference in the world, coupled with his drive to develop and deliver innovative products that improve patients’ lives, makes him an invaluable asset to KBI.”
“I am thrilled to join KBI Biopharma during a time of significant evolution for the company,” said Peter Carbone, Chief Quality Officer of KBI Biopharma. “We are poised for remarkable advancements in the biopharma industry, and I look forward to working with this talented team to drive innovation, ensure quality, deliver exceptional results, and ultimately make a meaningful impact on patients’ lives worldwide.”
Prior to joining KBI, Peter led engineering, operations, and quality organizations at major pharmaceutical companies, including Bayer, Amgen, Allergan, Novartis, Acorda, and the Center of Breakthrough Medicines. He holds a BS in Chemical Engineering from Rensselaer Polytechnic Institute.
About KBI Biopharma, Inc.
KBI Biopharma, Inc., a JSR Life Sciences company, together with its affiliates, is a global contract development and manufacturing organization (CDMO) providing fully integrated, accelerated drug development and biologics manufacturing services and expertise to life science companies. As a global leader in mammalian cell line development, with best-in-class modular technology and highly specialized solutions, KBI enables the life sciences industry to rapidly discover, develop and commercialize innovative medicines and vaccines. With each of its 500+ client partners, KBI works closely to personalize and rapidly accelerate drug development programs.
Global partners are utilizing KBI’s technologies to advance more than 160 drug candidates in preclinical and clinical development and the manufacture of ten commercial products. Built upon a foundation of world-class analytics capabilities and extensive scientific and technical expertise, KBI delivers robust process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. Recognized for quality manufacturing, KBI helps partners advance drug candidates to the market. KBI serves its global partners with eight locations in Europe and the USA. More information is available at www.kbibiopharma.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240401053397/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
comforte AG Warns of Impending March 2025 PCI DSS 4.0 Compliance Deadline11.2.2025 10:41:00 CET | Press release
comforte AG, a global leader in data security, today urged global businesses to finalize their PCI DSS 4.0 plans, ahead of the compliance deadline which falls on 31 March 2025. PCI DSS 4.0 is a major new iteration of the Payment Card Industry Data Security Standard, which applies to any organization which stores, processes or transmits cardholder data. As such, it has an outsized impact on sectors such as financial services and retail. The latest version features over 50 new technical requirements including new rules around data protection mechanisms. A key focus for PCI DSS 4.0 is to encourage cybersecurity as a long-term, continuous process, which is why additional flexibility has been baked into the standard—allowing organizations to choose the security controls most suited to their business. comforte’s tokenization technology is a proven, format-preserving way to safeguard cardholder data in line with PCI DSS 4.0, while preserving data utility. Because sensitive data elements like
Xsolla and AppsFlyer Unveil Custom Integration to Boost Mobile Game Web Shop Performance11.2.2025 10:00:00 CET | Press release
Industry First Collaboration Introduces Cross-Platform Analytics as an Integrated Solution to Solve Mobile and Web Measurement Challenges for Game Developers Xsolla, a leading global video game commerce company, has partnered with AppsFlyer, the global leader in mobile measurement, attribution, and data analytics, in a first-in-the-gaming industry web shop collaboration. This enhancement of the Xsolla and AppsFlyer partnership provides game developers with improved insights and simplified activation for its Web Shop solution, which is available worldwide. It also introduces solutions to address cross-platform measurement and attribution challenges. The partnership includes two integration options: server-to-server (S2S) and web integrations for mobile games. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211661118/en/ (Graphic: Xsolla) Xsolla and AppsFlyer have collaborated closely for over a year to develop two custom in
Dragon Elements Breaks Free From Screens With LATIDO® Capsules11.2.2025 10:00:00 CET | Press release
SCALE Nanotech spins out Dragon Elements to bring graphene-based audiovisual technology to the XR and wearable electronics market SCALE Nanotech, an advanced R&D company based in Estonia, has announced the launch of its spinout Dragon Elements in Spain, marking a disruptive entry into the XR and wearable electronics sector. Dragon Elements is set to commercialize LATIDO® capsules, a revolutionary graphene-based technology designed to redefine human interaction with hardware by eliminating the need for traditional audio and video components. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250211733484/en/ The Birth of LATIDO®: A New Paradigm in Audiovisual Technology Derived from the Spanish word latido (heartbeat), LATIDO® encapsulates a radical shift in audiovisual hardware. Unlike conventional technology that requires separate components for sound and vision, LATIDO® harnesses millions of one-atom-thick graphene membranes t
Knauf Builds an Autonomous Supply Chain With Blue Yonder11.2.2025 10:00:00 CET | Press release
Global leader in building materials and construction systems chooses Blue Yonder to enhance supply chain agility and achieve strategic objectives leveraging AI and ML In the highly competitive and dynamic building materials and systems industry, manufacturers need to drive strategic growth and financial performance to succeed. That’s why Knauf, a globally leading manufacturer of building materials and construction systems, has chosen to deploy Blue Yonder Demand Planning, a cloud-native solution with cognitive capabilities that utilizes artificial intelligence (AI) and machine learning (ML). The solution will enable Knauf to gain access to industry-focused insights that enable faster decisioning and more precise forecasting to further transform its supply chain demand planning capabilities. The solution deployment is led by Blue Yonder Professional Services. Since 1932, Knauf has been synonymous with innovation, quality, and sustainability, boasting over 300 production sites in more th
KRAFTON Records All Time Highs in Sales (2.7098T KRW) and Operating Profit (1.1825T KRW) in 202411.2.2025 08:00:00 CET | Press release
Record-breaking earnings, with an average annual growth rate of sales reaching 20% over the past five yearsAims to hit 7T KRW in sales and double the corporate value by ‘securing a Big Franchise IP’Enhancing innovation in the global gaming industry via AI technology advancements KRAFTON, Inc. held an Investor Relations (IR) briefing on February 11, announcing its financial results for the fourth quarter and full year of 2024. According to consolidated financial statements under Korean International Financial Reporting Standards (K-IFRS), KRAFTON recorded 2.7098T KRW and operating profit (OP) of 1.1825T KRW for 2024, marking new all-time highs. These figures represent year-over-year (YoY) growth of 41.8% in sales and 54.0% in OP, driven by the continued expansion and sustainability of the PUBG IP, resulting in an average annual sales growth rate of 20% over the past five years. In the fourth quarter of 2024, KRAFTON recorded 617.6B KRW in sales and 215.5B KRW in OP, reflecting YoY incre
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom